FibroScan-aspartate transaminase: A superior non-invasive model for diagnosing high-risk metabolic dysfunction-associated steatohepatitis

Table 1 Histopathological scoring of liver in the overall population, n (%)

NAS and fibrosis stage	Overall population (n = 279)	High-risk MASH group (n = 93)	Non-high-risk MASH group (n = 186)
NAS
0-3	52.0 (18.6)	0.0 (0.0)	52.0 (28.0)
≥ 4	227.0 (81.4)	93.0 (100.0)	134.0 (72.0)
Fibrosis stage
F0	11.0 (3.9)	0.0 (0.0)	11.0 (5.9)
F1	169.0 (60.6)	0.0 (0.0)	169.0 (90.9)
F2	65.0 (23.3)	61.0 (65.6)	4.0 (2.2)
F3	25.0 (9.0)	24.0 (25.8)	1.0 (0.5)
F4	9.0 (3.2)	8.0 (8.6)	1.0 (0.5)

NAS: Non-alcoholic fatty liver disease activity score; MASH: Metabolic dysfunction-associated steatohepatitis.